Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 11;24(2):210-218.
doi: 10.17305/bb.2023.9518.

Stem cell therapy for degenerative disc disease: Bridging the gap between preclinical promise and clinical potential

Matic Munda  1 , Tomaz Velnar  2
Affiliations
Review

Stem cell therapy for degenerative disc disease: Bridging the gap between preclinical promise and clinical potential

Matic Munda et al. Biomol Biomed. .

Abstract

Stem cell therapy has gained attention in the field of regenerative medicine due to its potential to restore damaged tissue. This article focuses on the application of stem cell therapy for treating spinal pathologies, particularly intervertebral disc degeneration. Disc degeneration is a major cause of low back pain and is characterized by changes in the matrix and inflammation. Animal studies have demonstrated that the implantation of mesenchymal stem cells (MSCs) yields promising results, including increased disc height, improved hydration, and reduced inflammation. However, the number of clinical trials remains limited, necessitating further research to optimize MSCs therapy. Although preclinical studies offer valuable insights, caution is needed when extrapolating these findings to clinical practice. Stem cell therapy still faces multiple challenges, such as the durability and survival of MSCs upon implantation, uncertain pathways to discogenic differentiation, and the adverse impact of a harsh microenvironment on cell survival. The avascular nature of the intervertebral disc and dynamic loading conditions also affect the adaptation of transplanted cells. Despite these obstacles, stem cell therapy holds promise as a potential treatment for disc degeneration, and ongoing research aims to fill the current gap in conclusive data.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Pathways of cellular differentiation and stem cell lineages.
Figure 2.
Figure 2.
Factors influencing the survival of implanted stem cells.
See this image and copyright information in PMC

References

    1. Schroeder J, Kueper J, Leon K, Liebergall M. Stem cells for spine surgery. World J Stem Cells. 2015 Jan 26;7(1):186–94. https://doi.org/10.4252/wjsc.v7.i1.186. - PMC - PubMed
    1. Richardson SM, Kalamegam G, Pushparaj PN, Matta C, Memic A, Khademhosseini A, et al. Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration. Methods. 2016 Apr 15;99:69–80. https://doi.org/10.1016/j.ymeth.2015.09.015. - PubMed
    1. Szymoniuk M, Litak J, Sakwa L, Dryla A, Zezuliński W, CzyŻewski W, et al. Molecular mechanisms and clinical application of multipotent stem cells for spinal cord injury. Cells. 2022 Dec 28;12(1):120. https://doi.org/10.3390/cells12010120. - PMC - PubMed
    1. Teixeira GQ, Pereira CL, Ferreira JR, Maia AF, Gomez-Lazaro M, Barbosa MA, et al. Immunomodulation of human mesenchymal stem/stromal cells in intervertebral disc degeneration: insights from a proinflammatory/degenerative ex vivo model. Spine (Phila Pa 1976) 2018 Jun 15;43(12):E673–E82. https://doi.org/10.1097/BRS.0000000000002494. - PubMed
    1. Genc B, Bozan HR, Genc S, Genc K. Stem cell therapy for multiple sclerosis. Adv Exp Med Biol. 2019;1084:145–74. https://doi.org/10.1007/5584/_2018/_247. - PubMed

MeSH terms